| Name | MYCi361 |
| Description | MYCi361 (NUCC-0196361) is an inhibitor of MYC (binding to MYC with Kd of 3.2 μM). |
| Animal Research | FVB or NSG male mice of 6-8 weeks of age and 25 g bearing established MycCaP tumors.MYCi361 treatment i.p. initially at 50 mg/kg twice daily for 2 days, then 70 mg/kg/day for 9 days |
| In vitro | MYCi361 is a small-molecule MYC inhibitors that inhibits the viability of MYC-dependent cancer cells including prostate cancer (MycCaP, LNCaP, and PC3), leukemia (MV4-11), lymphoma (HL-60 and P493-6), and neuroblastoma (SK-N-B2) with low-micromolar IC50 values[1]. |
| In vivo | MYC inhibitor 361 (MYCi361), suppressed in vivo tumor growth in mice, increased tumor immune cell infiltration, upregulated PD-L1 on tumors, and sensitized tumors to anti-PD1 immunotherapy. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 100 mg/mL (168.11 mM), Sonication is recommended. 10% DMSO+90% Corn Oil : 3.3 mg/mL (5.55 mM), Sonication is recommended.
|
| Keywords | NUCC0196361 | NUCC 0196361 | MYCi-361 | MYCi361 | MYCi 361 | MYC | Inhibitor | inhibit | c-Myc | cMyc |
| Inhibitors Related | 6K465 | Mollugin | NY2267 | VPC-70063 | KJ Pyr 9 | Mycro 3 | 10058-F4 | MC-1-F2 | DK419 | RK-9123016 | MYCi975 | Nicotinamide N-oxide |
| Related Compound Libraries | Glycolysis Compound Library | Bioactive Compound Library | Hematonosis Compound Library | Glutamine Metabolism Compound Library | Anti-Cancer Metabolism Compound Library | Inhibitor Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Cell Cycle Compound Library | Wnt/Hedgehog/Notch Compound Library | Anti-Cancer Active Compound Library | Transcription Factor-Targeted Compound Library |